tipifarnib has been researched along with fulvestrant in 1 studies
Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (fulvestrant) | Trials (fulvestrant) | Recent Studies (post-2010) (fulvestrant) |
---|---|---|---|---|---|
309 | 92 | 94 | 2,712 | 207 | 1,196 |
Protein | Taxonomy | tipifarnib (IC50) | fulvestrant (IC50) |
---|---|---|---|
Estrogen receptor | Homo sapiens (human) | 0.0061 | |
Estrogen receptor | Rattus norvegicus (Norway rat) | 0.0059 | |
Progesterone receptor | Homo sapiens (human) | 0.0002 | |
Steroid hormone receptor ERR1 | Homo sapiens (human) | 0.002 | |
Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | 0.006 | |
Estrogen receptor beta | Homo sapiens (human) | 0.0104 | |
Bile acid receptor | Homo sapiens (human) | 0.79 | |
NAD-dependent protein deacylase sirtuin-5, mitochondrial | Homo sapiens (human) | 2.6 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Christos, PJ; Hershman, DL; Hoschander, S; Li, T; O'Brien, K; Sparano, JA; Vahdat, LT; Wright, JJ | 1 |
1 trial(s) available for tipifarnib and fulvestrant
Article | Year |
---|---|
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Farnesyltranstransferase; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Quinolones; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2009 |